HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+12.56%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$2.18B
AUM Growth
+$2.18B
(+25%)
Cap. Flow
+$297M
Cap. Flow
% of AUM
13.64%
Top 10 Holdings %
Top 10 Hldgs %
65.42%
Holding
52
New
13
Increased
11
Reduced
11
Closed
14
Top Buys
| 1 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
$272M |
| 2 |
Edwards Lifesciences
EW
|
$118M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$112M |
| 4 |
AET
Aetna Inc
AET
|
$93.9M |
| 5 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$83.5M |
Top Sells
| 1 |
Quest Diagnostics
DGX
|
$103M |
| 2 |
QGENF
QIAGEN NV
QGENF
|
$79.9M |
| 3 |
Danaher
DHR
|
$75.8M |
| 4 |
Incyte
INCY
|
$74.3M |
| 5 |
Zimmer Biomet
ZBH
|
$69.6M |
Sector Composition
| 1 | Healthcare | 87.1% |
| 2 | Financials | 9.22% |
| 3 | Materials | 1.56% |
| 4 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Medpace
MEDP
$13.5B
| $20.9M | 0.96% |
700,000
+275,000
| +65% | +$8.21M |
|
|
CLVS
27
DELISTED
Clovis Oncology, Inc.
CLVS
| $19.1M | 0.88% |
300,000
-325,000
| -52% | -$20.7M |
|
28
DexCom
DXCM
$30.9B
| $19.1M | 0.87% |
900,000
-614,600
| -41% | -$13M |
|
|
BCR
29
DELISTED
CR Bard Inc.
BCR
| $19M | 0.87% |
76,560
-30,810
| -29% | -$7.66M |
|
30
Medtronic
MDT
$118B
| $17.2M | 0.79% |
+213,030
| New | +$17.2M |
|
|
AKRX
31
DELISTED
Akorn, Inc.
AKRX
| $15.7M | 0.72% |
+650,000
| New | +$15.7M |
|
32
Cigna
CI
$80.2B
| $14.8M | 0.68% |
100,720
-329,420
| -77% | -$48.3M |
|
|
JUNO
33
DELISTED
Juno Therapeutics, Inc.
JUNO
| $11.7M | 0.53% |
+525,000
| New | +$11.7M |
|
|
34
Danaher
DHR
$143B
| $10.1M | 0.46% |
133,307
-999,938
| -88% | -$75.8M |
|
|
35
Quest Diagnostics
DGX
$20.1B
| $7.76M | 0.36% |
78,982
-1,046,018
| -93% | -$103M |
|
36
Becton Dickinson
BDX
$54.3B
| $4.51M | 0.21% |
+25,174
| New | +$4.51M |
|
37
BioMarin Pharmaceuticals
BMRN
$11.3B
| – | – |
-775,000
| Closed | -$64.2M |
|
38
Collegium Pharmaceutical
COLL
$1.25B
| – | – |
-1,426,300
| Closed | -$22.2M |
|
39
Encompass Health
EHC
$12.5B
| – | – |
-1,257,659
| Closed | -$41.3M |
|
40
Amicus Therapeutics
FOLD
$2.42B
| – | – |
0
| – | – |
|
41
Gilead Sciences
GILD
$140B
| – | – |
0
| – | – |
|
42
Globus Medical
GMED
$7.94B
| – | – |
-450,000
| Closed | -$11.2M |
|
43
Hologic
HOLX
$14.7B
| – | – |
-452,340
| Closed | -$18.1M |
|
|
44
Incyte
INCY
$17B
| – | – |
-741,360
| Closed | -$74.3M |
|
45
Natera
NTRA
$23B
| – | – |
-299,300
| Closed | -$3.51M |
|
46
Revvity
RVTY
$9.68B
| – | – |
-44,150
| Closed | -$2.3M |
|
47
Thermo Fisher Scientific
TMO
$183B
| – | – |
-94,980
| Closed | -$13.4M |
|
|
48
Zimmer Biomet
ZBH
$20.8B
| – | – |
-695,003
| Closed | -$69.6M |
|
|
SPNE
49
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| – | – |
-641,700
| Closed | -$5.07M |
|
|
PRAH
50
DELISTED
PRA Health Sciences, Inc.
PRAH
| – | – |
-300,000
| Closed | -$16.5M |
|